Metabolic syndrome as a nexus of diabetes and cardiovascular disease: pathophysiological insights, epidemiological evidence, and therapeutic implications

Abstract

Metabolic Syndrome (MetS) constitutes a constellation of interrelated abnormalities: central obesity, insulin resistance, dyslipidemia, hypertension, and impaired fasting glucose that collectively heighten the risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). This thesis critically examines the pathophysiological mechanisms, epidemiological trends, and therapeutic strategies associated with MetS, underscoring its role as a pivotal nexus between T2DM and CVD. Key pathogenic drivers include visceral adiposity, chronic low-grade inflammation, and mitochondrial dysfunction, which perpetuate insulin resistance and metabolic imbalance. Epidemiological data emphasizes the global burden of MetS, its strong association with T2DM and CVD, and the necessity of early detection through criteria such as those established by the IDF and NCEP ATP III. Current interventions encompass lifestyle modification, pharmacotherapy (statins, SGLT2 inhibitors, GLP-1 receptor agonists), and nutraceuticals. Emerging precision medicine approaches, including metabolomics and proteomics, promise individualized therapy. Future perspectives should explore genetic susceptibility, epigenetic regulation, and gut microbiome interactions.